

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Jabbour et al.)	
)	Examiner:
Serial No:	10/511,480)	M. L. Sznaidman
)	
Cnfrm. No.:	6559)	
)	
Filed:	April 10, 2003)	Art Unit:
)	1609
For :	FP RECEPTOR ANTAGONISTS OR PGF2)	
	ALPHA ANTAGONISTS FOR TREATING)	
	PATHOLOGICAL CONDITIONS OF THE)	
	UTERUS)	

RESPONSE TO RESTRICTION AND ELECTION OF SPECIES REQUIREMENTS

Mail Stop: **Amendment**
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the July 31, 2007, written restriction requirement, applicants hereby elect Group I (i.e., claims 1-18) with traverse. Applicants traverse the restriction requirement on the basis that all of Groups I-III are closely related and can be searched without undue burden. Therefore, the restriction requirement should be withdrawn.

In response to the species election set forth on pages 3-4 of the outstanding office action, applicants hereby elect with traverse the following species: (1) an agent that prevents PGF2 α having its effect on the FP receptor; and (1a) an agent that is an antagonist of the FP receptor. The particular species of (1a), recited in Claim 9, is AL-8810. Claims of Group I reading on the species AL-8810 include Claims 1-9 and 12-18. Applicants hereby traverse the election of species requirement, in part, on the basis that the shared functional activity among species of subgenus (1a) justifies search and examination of this entire subgenus.

For the above reasons, applicants respectfully request that the written restriction requirement and election of species requirements be withdrawn in whole or in part for the reasons set forth above.

Respectfully submitted,

Date: August 22, 2007

/Edwin V. Merkel/
Edwin V. Merkel
Registration No. 40,087

Nixon Peabody LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603
Telephone: (585) 263-1128
Facsimile: (585) 263-1600